Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod.

de Jong BA, van Kempen ZLE, Wattjes MP, Smit PM, Peferoen L, Berry D, Chamuleau MED, de Jong D.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 10;5(5):e483. doi: 10.1212/NXI.0000000000000483. eCollection 2018 Sep. No abstract available.

2.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

3.

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

van Kempen ZL, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):822-823. doi: 10.1177/1352458517734073. Epub 2017 Oct 9. No abstract available.

4.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2018 Oct;24(11):1453-1460. doi: 10.1177/1352458517726381. Epub 2017 Aug 21.

5.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
6.

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.

7.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019

Supplemental Content

Loading ...
Support Center